siRNA Targeting MAPT Exon 10 for Selective Tau Silencing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA interference methods for treating neurodegenerative diseases associated with abnormalities in the MAPT gene encoded protein tau, such as FTDP-17, face challenges in selectively silencing mutant tau alleles without depleting the wild-type allele, and existing approaches for correcting Exon 10 inclusion have low efficiency or non-specificity.
Innovation Solution
The use of specific siRNAs targeting the MAPT gene exon 10 sequence, designed to induce selective degradation of exon 10-containing MAPT transcripts, which are administered as a therapeutic agent to treat neurodegenerative diseases like Alzheimer's, Huntington's, and Parkinson's, using a double-strand RNA composition with complementary sense and antisense strands and optional overhangs for enhanced stability and efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If siRNA is used to suppress MAPT gene expression, then tau protein levels are reduced, but selective silencing of mutant alleles without depleting wild-type allele is difficult to achieve
Solution Approach 1:
The siRNA is designed to target a specific local region (Exon 10) of the MAPT gene that is abnormal in mutant alleles. By focusing the silencing action on this particular exon rather than the entire gene, the invention achieves selective degradation of mutant transcripts containing Exon 10 while preserving wild-type transcripts that lack this exon or have normal splicing patterns.
Solution Approach 2:
The invention segments the target gene into functional regions by specifically targeting Exon 10, which is the problematic segment in mutant alleles. This segmentation allows the siRNA to distinguish between mutant and wild-type transcripts based on the presence or absence of this specific exon, enabling selective silencing without affecting the entire gene expression.
2Productivity
If existing approaches for correcting Exon 10 inclusion are used, then splicing modulation is achieved, but efficiency is low and specificity is poor
Solution Approach 1:
The invention replaces mechanical/small molecule-based splicing modulation approaches with an RNA interference mechanism. Instead of using small molecules that non-specifically affect splicing, the siRNA provides a sequence-specific molecular mechanism that directly binds to and degrades mutant transcripts containing Exon 10, achieving both high efficiency and high specificity simultaneously.
Solution Approach 2:
The siRNA acts as an intermediary molecule that specifically recognizes and binds to the abnormal Exon 10 sequence in mutant transcripts. This intermediary approach allows for precise targeting of the mutant allele through base pairing, enabling efficient and specific correction of the splicing defect without affecting wild-type gene expression.
3Adaptability or versatility
If cardiotonic steroids are used as exon 10 splicing modulators, then splicing is modulated, but the approach is non-specific
Solution Approach 1:
The siRNA targets a specific local sequence within Exon 10 of the MAPT gene, providing highly specific modulation of splicing. Unlike cardiotonic steroids that act non-specifically on splicing machinery, the siRNA's sequence complementarity ensures it only binds to and degrades transcripts containing the specific mutant Exon 10 sequence, achieving both adaptability and reliability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The siRNA-based therapy effectively reduces exon 10-containing MAPT transcripts, restoring the normal 4Rtau/3Rtau ratio, demonstrating therapeutic potential by selectively degrading mutant transcripts without affecting wild-type alleles, as validated in cell models recapitulating FTDP-17 conditions and other neurodegenerative diseases.
Implementation Method 1
methods have been developed to trigger RNA interference (RNAi) against specific targets in mammalian cells by introducing exogenously produced or intra-cellularly expressed small interfering RNA (siRNA) molecules
Data Source
Figure 1~2B
Figure 3~4
Figure 5
AI summary
Therapeutic agent for use in the treatment of neurodegenerative diseases associated with abnormalities of MAPT gene encoded protein tau, wherein said therapeutic agent comprises one or more siRNAs targeting MAPT exon 10 sequence.